* Vivos Therapeutics Inc reported a quarterly adjusted loss of 40 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.62. The mean expectation of two analysts for the quarter was for a loss of 61 cents per share.
* Revenue rose 16.9% to $3.86 million from a year ago; analysts expected $4.06 million.
* Vivos Therapeutics Inc's reported EPS for the quarter was a loss of 40 cents.
* The company reported a quarterly loss of $2.62 million.
* Vivos Therapeutics Inc shares had risen by 19.5% this quarter and lost 74.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 36.5% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"
Wall Street's median 12-month price target for Vivos Therapeutics Inc is 7.43 This summary was machine generated from LSEG data November 15 at 02:13 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.61 -0.40 Beat
Jun. 30 2024 -1.05 -0.60 Beat
Mar. 31 2024 -1.17 -1.63 Missed
Dec. 31 2023 -1.90 -3.05 Missed
Comments